Loading organizations...
NSG Ventures operates as a global biotech venture capital firm, investing in innovative solutions to combat human diseases. The firm employs a founder-led strategy, partnering with exceptional teams to advance medical breakthroughs. Its leadership, composed of experienced scientists and entrepreneurs, guides portfolio companies with sector knowledge.
Co-founded by Daphne Teo, Timothy Lu, and Jeffrey Lu around 2020, NSG Ventures originated from their collective insight into the need for hands-on, expert-driven support in life sciences. Daphne Teo, an accomplished investor, joined Timothy Lu, a distinguished synthetic biology expert and serial biotech entrepreneur. Their combined pedigree offers strategic guidance to nascent ventures.
NSG Ventures empowers biotech companies developing solutions for complex health challenges. Their vision is to accelerate scientific discoveries into impactful medical technologies. By providing capital, strategic mentorship, and access to its ecosystem, including NSG BioLabs, the firm cultivates the next generation of biotech innovators, fostering transformative therapies.
NSG Ventures has 3 tracked investments across 2 companies. The latest tracked deal is $21.0M Series A in GDMC in January 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 26, 2024 | GDMC | $21.0M Series A | Celadon Partners | Seeds Capital, WI Harper Group |
| Nov 25, 2021 | Lunit | $61.0M Other Equity | — | Brightedge Ventures, Casdin Capital, Guardant Health, HealthQuest Capital, Tybourne Capital Management |
| Nov 1, 2021 | Lunit | $61.0M Series U | — | A7V, Alpine Ventures, Goodwater Capital, HealthQuest Capital, NextGen Venture Partners, Ontario Teachers' Pension Plan, Brightedge Ventures, Casdin Capital, Guardant Health, Tybourne Capital Management |
